Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

Benzinga · 1d ago
Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $76 price target.